Previous 10 | Next 10 |
Image source: The Motley Fool. Icon PLC (NASDAQ: ICLR) Q3 2020 Earnings Call Oct 22, 2020 , 9:00 a.m. ET Operator Continue reading For further details see: Icon PLC (ICLR) Q3 2020 Earnings Call Transcript
ICON Public Limited Company (ICLR) Q3 2020 Earnings Conference Call October 22, 2020 09:00 AM ET Executives Jonathan Curtain - VP Corporate Finance & IR Steve Cutler - CEO Brendan Brennan - CFO Analysts David Windley - Jefferies Patrick Donnelly - Citigroup Elizabeth Anderson - Evercore R...
Icon (ICLR): Q3 GAAP EPS of $1.72 beats by $0.12.Revenue of $701.73M (-1.2% Y/Y) beats by $31.63M.Raising FY 2020 revenue guidance to a range of $2,750-$2,810M and EPS in the range of $6.35-$6.50.Shares +4.83%.Press Release For further details see: Icon EPS beats by $0.12, beats on reve...
Highlights Record net business wins in the quarter of $990 million; a book to bill of 1.41. Record closing backlog of $9.4 billion, an increase of 11.8% year on year. Quarter 3 reported revenue of $701.7 million representing a year on year decrease of 1.2% and ...
Icon (NASDAQ:ICLR) is scheduled to announce Q3 earnings results on Wednesday, October 21st, after market close.The consensus EPS Estimate is $1.57 (-9.8% Y/Y) and the consensus Revenue Estimate is $670.1M (-5.7% Y/Y).Over the last 2 years, ICLR has beaten EPS estimates 50% of the time and has...
Award recognises ICON’s long-standing vaccine development expertise ICON plc, (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries and government a...
Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biote...
ICON plc , (NASDAQ: ICLR) a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that: Mr. Brendan Brennan, CFO of ICON plc, will present...
ICON recognised as top employer for women in anonymous survey of 75,000 employees ICON plc, (NASDAQ: ICLR) a leading global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries today announced that it has been...
Any potential coronavirus treatment or vaccine could run through ICON ( ICLR ), a large clinical-research organization (CRO) that helps pharmaceutical companies develop new medications, asserts Richard Moroney , editor of Dow Theory Forecasts . The company focuses on lat...
News, Short Squeeze, Breakout and More Instantly...
Highlights Net business wins in the quarter of $2,579 million, an increase of 6.6% on quarter two 2023. Reflects a net book to bill in the quarter of 1.22, and a trailing twelve month net book to bill of 1.24. Closing backlog of $23.8 billion, an increase of 2.0% on quarter one 20...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 23, 2024 were duly passed by shareholders. ICON also confirmed that following the conclus...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...